Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics.

Our mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs.

Nanoligent uses state-of-the-art protein engineering and nanobiotechnology to develop targeted drug therapy. Our technology allows the design of new protein conjugates organized as nanoparticles and capable of targeting specific biological systems. This protein architecture is highly stable upon administration in vivo, allowing not only long-lasting systemic circulation but also site-specific drug delivery. Precision medicine aiming high therapeutic index and low side effects for oncology.

Our proteins have the capacity to self-assamble and form nanoparticles that avoid kidney clearance.
By means of a specific ligand, Nanoligent’s medicine is able to selectively target cells, delivering the desired cargo.

We have developed humanized scaffolds for our medicine to avoid undesired immune responses.

Our technology involves protein-only nanoparticles that can be degraded naturally in the body.
Drug conjugation allow our nanoparticles to kill cells while retaining the selectivity. Thus, there is a reduction in systemic toxicity.